Current treatment and clinical trial developments for ductal carcinoma in situ of the breast

Judy C Boughey, Ricardo J. Gonzalez, Everett Bonner, Henry M. Kuerer

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Ductal carcinoma in situ (DCIS) is the fastest growing subtype of breast cancer, mainly because of the aging of our populations and improvements in diagnostic mammography and core biopsy. DCIS represents a proliferation of malignant-appearing cells that have not invaded beyond the ductal basement membrane and is a precursor for the development of invasive breast cancer (IBC). Approximately 40% of patients with DCIS treated with biopsy alone, without complete excision or further therapy, develop IBC. Most DCIS itself is harmless if it is detected and excised before it can progress to IBC, and the current approach to DCIS treatment is aimed at just that goal. Typically, it consists of multimodal treatment including segmental mastectomy followed by radiation therapy to the whole breast and then hormonal therapy or total mastectomy followed by hormonal therapy. This review discusses the state-of-the-art in DCIS detection and treatment and highlights promising new strategies in the care of DCIS patients. The data regarding the effectiveness of breast-conserving surgery versus total mastectomy, the possible avoidance of radiation therapy in some subgroups of patients, and the role of hormonal agents are reviewed. Neoadjuvant therapy and the use of trastuzumab for DCIS are currently under investigation and may be future treatment options for DCIS.

Original languageEnglish (US)
Pages (from-to)1276-1287
Number of pages12
JournalOncologist
Volume12
Issue number11
DOIs
StatePublished - Nov 2007

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Breast
Clinical Trials
Simple Mastectomy
Breast Neoplasms
Therapeutics
Segmental Mastectomy
Radiotherapy
Biopsy
Combined Modality Therapy
Neoadjuvant Therapy
Mammography
Basement Membrane

Keywords

  • Ductal carcinoma in situ
  • Radiation
  • Tamoxifen
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. / Boughey, Judy C; Gonzalez, Ricardo J.; Bonner, Everett; Kuerer, Henry M.

In: Oncologist, Vol. 12, No. 11, 11.2007, p. 1276-1287.

Research output: Contribution to journalArticle

Boughey, Judy C ; Gonzalez, Ricardo J. ; Bonner, Everett ; Kuerer, Henry M. / Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. In: Oncologist. 2007 ; Vol. 12, No. 11. pp. 1276-1287.
@article{56cb82e7943e4516aaabed5fa79b1962,
title = "Current treatment and clinical trial developments for ductal carcinoma in situ of the breast",
abstract = "Ductal carcinoma in situ (DCIS) is the fastest growing subtype of breast cancer, mainly because of the aging of our populations and improvements in diagnostic mammography and core biopsy. DCIS represents a proliferation of malignant-appearing cells that have not invaded beyond the ductal basement membrane and is a precursor for the development of invasive breast cancer (IBC). Approximately 40{\%} of patients with DCIS treated with biopsy alone, without complete excision or further therapy, develop IBC. Most DCIS itself is harmless if it is detected and excised before it can progress to IBC, and the current approach to DCIS treatment is aimed at just that goal. Typically, it consists of multimodal treatment including segmental mastectomy followed by radiation therapy to the whole breast and then hormonal therapy or total mastectomy followed by hormonal therapy. This review discusses the state-of-the-art in DCIS detection and treatment and highlights promising new strategies in the care of DCIS patients. The data regarding the effectiveness of breast-conserving surgery versus total mastectomy, the possible avoidance of radiation therapy in some subgroups of patients, and the role of hormonal agents are reviewed. Neoadjuvant therapy and the use of trastuzumab for DCIS are currently under investigation and may be future treatment options for DCIS.",
keywords = "Ductal carcinoma in situ, Radiation, Tamoxifen, Trastuzumab",
author = "Boughey, {Judy C} and Gonzalez, {Ricardo J.} and Everett Bonner and Kuerer, {Henry M.}",
year = "2007",
month = "11",
doi = "10.1634/theoncologist.12-11-1276",
language = "English (US)",
volume = "12",
pages = "1276--1287",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "11",

}

TY - JOUR

T1 - Current treatment and clinical trial developments for ductal carcinoma in situ of the breast

AU - Boughey, Judy C

AU - Gonzalez, Ricardo J.

AU - Bonner, Everett

AU - Kuerer, Henry M.

PY - 2007/11

Y1 - 2007/11

N2 - Ductal carcinoma in situ (DCIS) is the fastest growing subtype of breast cancer, mainly because of the aging of our populations and improvements in diagnostic mammography and core biopsy. DCIS represents a proliferation of malignant-appearing cells that have not invaded beyond the ductal basement membrane and is a precursor for the development of invasive breast cancer (IBC). Approximately 40% of patients with DCIS treated with biopsy alone, without complete excision or further therapy, develop IBC. Most DCIS itself is harmless if it is detected and excised before it can progress to IBC, and the current approach to DCIS treatment is aimed at just that goal. Typically, it consists of multimodal treatment including segmental mastectomy followed by radiation therapy to the whole breast and then hormonal therapy or total mastectomy followed by hormonal therapy. This review discusses the state-of-the-art in DCIS detection and treatment and highlights promising new strategies in the care of DCIS patients. The data regarding the effectiveness of breast-conserving surgery versus total mastectomy, the possible avoidance of radiation therapy in some subgroups of patients, and the role of hormonal agents are reviewed. Neoadjuvant therapy and the use of trastuzumab for DCIS are currently under investigation and may be future treatment options for DCIS.

AB - Ductal carcinoma in situ (DCIS) is the fastest growing subtype of breast cancer, mainly because of the aging of our populations and improvements in diagnostic mammography and core biopsy. DCIS represents a proliferation of malignant-appearing cells that have not invaded beyond the ductal basement membrane and is a precursor for the development of invasive breast cancer (IBC). Approximately 40% of patients with DCIS treated with biopsy alone, without complete excision or further therapy, develop IBC. Most DCIS itself is harmless if it is detected and excised before it can progress to IBC, and the current approach to DCIS treatment is aimed at just that goal. Typically, it consists of multimodal treatment including segmental mastectomy followed by radiation therapy to the whole breast and then hormonal therapy or total mastectomy followed by hormonal therapy. This review discusses the state-of-the-art in DCIS detection and treatment and highlights promising new strategies in the care of DCIS patients. The data regarding the effectiveness of breast-conserving surgery versus total mastectomy, the possible avoidance of radiation therapy in some subgroups of patients, and the role of hormonal agents are reviewed. Neoadjuvant therapy and the use of trastuzumab for DCIS are currently under investigation and may be future treatment options for DCIS.

KW - Ductal carcinoma in situ

KW - Radiation

KW - Tamoxifen

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=36849024827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849024827&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.12-11-1276

DO - 10.1634/theoncologist.12-11-1276

M3 - Article

C2 - 18055847

AN - SCOPUS:36849024827

VL - 12

SP - 1276

EP - 1287

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 11

ER -